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Objectives This study sought to evaluate the technical success and clinical outcomes of an adjunc-
tive crossover balloon occlusion technique (CBOT) combined with the 10-F Prostar percutaneous
closure device (PCD) on the incidence of vascular and bleeding complications in patients after trans-
femoral transcatheter aortic valve implantation (TAVI).
Background Vascular closure following large-vessel access has most commonly been performed
using a surgical cut-down and repair procedure.
Methods Between November 2008 and September 2010, 58 consecutive patients with severe aortic
stenosis underwent TAVI via a retrograde femoral artery approach using the Edwards-SAPIEN trans-
catheter valve. Among these patients, 56 were treated with a CBOT using the “pre-close” technique
and the 10-F Prostar system. The technical success of this new CBOT and the 30-day frequency of
clinical events, including all-cause mortality, major vascular complications, and major bleeding (de-
ﬁned according to a modiﬁed version of the Valve Academic Research Consortium criteria), were
assessed.
Results Successful closure was obtained in all but 3 patients (94.6%). The 30-day frequencies of
mortality, major vascular complications, and major bleeding were 7.1%, 14.3%, and 5.4% respec-
tively. No deaths were directly related to access site complications. Fourteen patients (25%) received
at least 1 transfusion during the index hospitalization, of which 8 (57.1%) were not related to vascu-
lar complications. The mean and median hospital lengths of stay were 7.8 and 6.0 days.
Conclusions This new percutaneous adjunctive CBOT combined with the Prostar PCD resulted in
controlled, safe, and successful percutaneous closure in most patients after TAVI. (J Am Coll
Cardiol Intv 2011;4:861–7) © 2011 by the American College of Cardiology Foundation
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862Transcatheter aortic valve implantation (TAVI) has been
increasingly recognized as an alternative therapeutic option
for patients with severe aortic stenosis (AS) and cardiac
symptoms (1–4). Recently, the first multicenter, random-
ized controlled trial of TAVI in patients with severe AS
who were not suitable candidates for surgery demonstrated
that transfemoral, balloon-expandable TAVI reduced mor-
tality and cardiac symptoms compared with standard ther-
apy (5). However, vascular and bleeding complications were
frequent in this randomized trial (PARTNER [Placement
of Aortic Transcatheter Valves]) and in other studies, and
represent a significant limitation of transfemoral TAVI
(6–8). Due to the combination of large-diameter delivery
systems and diseased peripheral vasculature in these elderly
patients with AS, an elective surgical approach to vascular
access and closure was the strategy of choice in the early
TAVI experience. More recently, fully percutaneous tech-
niques have been explored in suitable patients, and if safe
and effective, may be the preferred alternative to reduce local
access site complications and to accelerate patient ambula-
tion. Although both the 10-F Prostar percutaneous closure
device (PCD) (Abbott Vascular
Inc., Santa Clara, California) and
PerClose Proglide (Abbott Vascu-
lar) devices have been used for per-
cutaneous closure involving large
sheaths, these devices have been as-
sociated with serious adverse out-
comes in cases of device failure
(9–14). To improve percutaneous
large-sheath access site closure, an
adjunctive crossover balloon occlu-
sion technique (CBOT) was devel-
oped and tested in patients after TAVI procedures (15,16). The
purpose of this report is to assess the technical success and clinical
outcomes after CBOT combined with the 10-F Prostar PCD in
a consecutive series of suitable patients undergoing TAVI proce-
dures via the transfemoral approach.
Methods
Patient population. Between November 2008 and Septem-
ber 2010, a total of 58 consecutive patients with severe AS
underwent TAVI via the retrograde femoral artery approach
using a 23- or 26-mm Edwards SAPIEN transcatheter
valve (22- or 24-F sheath, respectively) as part of the
PARTNER trial. Fifty-six of these patients were systemat-
ically treated with CBOT and a Prostar PCD system; 2
others underwent an elective surgical repair due to femoral
artery pathoanatomy that was unsuitable for percutaneous
closure. TAVI and CBOT were performed by an experi-
enced team composed of interventional cardiologists and
Abbreviations
and Acronyms
AS  aortic stenosis
CBOT  crossover balloon
occlusion technique
PCD  percutaneous closure
device
TAVI  transcatheter aortic
valve implantationcardiothoracic surgeons at a single center (Columbia sUniversity Medical Center/New York Presbyterian Hos-
pital, New York, New York).
Description of the CBOT. CBOT was systematically performed
n each patient according to the following steps (Fig. 1): 1)
uoroscopy-guided puncture of the common femoral artery
ollowing angiographic localization of the “ideal” entry site
ith an iliac angiogram; 2) insertion and deployment of a
0-F Prostar PCD to “pre-close” the vessel; 3) transfemoral
lacement of the delivery sheath, then TAVI performed,
nd TAVI delivery catheter removed; 4) delivery sheath
ithdrawn into the common iliac artery over a 0.035-inch
-tip guidewire; 5) using a hydrophilic guidewire (J-Tip
lidewire, Terumo Medical Corporation, Somerset, New
ersey) from the contralateral side, a crossover catheter (Accu-Vu
mni Flush,AngioDynamics, Latham,NewYork)was advanced
nto the TAVI delivery sheath; 6) a stiff 0.035-inch guide-
ire was advanced through the crossover catheter and into
he TAVI delivery sheath; 7) the crossover catheter was
xchanged for a long crossover sheath (7-F or 8-F); 8)
rostar PCD sutures are tied as described in the conven-
ional manner; 9) the TAVI delivery sheath was withdrawn
radually to just above the arteriotomy site while performing
ntermittent contrast injections through the crossover sheath to
ssess vascular injury; 10) a peripheral balloon (8 to 12 mm in
iameter depending on common femoral or external iliac size)
s inserted through the crossover sheath and inflated at low
ressures (0.5 atm) just above the TAVI delivery sheath to
llow a nontraumatic occlusion of the vessel before knot
elivery; 11) the TAVI delivery sheath was removed and knots
dvanced to the arteriotomy; 12) peripheral balloon was de-
ated and hemostasis assessed via injection through crossover
heath; 13) if needed, a hydrophilic wire from the contralateral
ite was used to cross the puncture site and was positioned in
he superficial femoral artery. The peripheral balloon was then
dvanced over this wire and inflated at the arteriotomy site to
ptimize closure; and 14) withdrawal of the wire, balloon, and
rossover sheath.
Endpoints and deﬁnitions. The technical success of CBOT
ascular closure was defined as the absence of significant early
during the procedure) or late (after the procedure) arteriotomy
ite complications requiring an unplanned surgical repair. We
lso assessed the 30-day frequency of all-cause mortality, major
ascular complications, and major bleeding complications,
efined according to a modified version of the Valve Academic
esearch Consortium criteria as described in the PARTNER
rial (5,15). Vascular complications included complications
riginating from the TAVI sheath (ipsilateral), contralateral
ite, or from any other origin. Other endpoints included mean
rop in hemoglobin, mean drop in hematocrit, number of
lood transfusions, and duration of hospitalization.
Major vascular complications were defined by the presence
f any of the following: 1) any thoracic aortic dissection;
) access site or access-related vascular injury (dissection,
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863eurysm, hematoma, irreversible nerve injury, or compartment
syndrome) leading to either death, need for significant blood
transfusions (3 U), unplanned percutaneous (endovascular
stent) or surgical intervention, or irreversible end organ dam-
age; 3) distal embolization (noncerebral) from a vascular source
requiring surgery or resulting in amputation or irreversible end
organ damage; or 4) left ventricular perforation.Minor vascular
complications were defined by the presence of any of the
following: 1) access site or access-related vascular injury (dis-
section, stenosis, perforation, rupture, arteriovenous fistula, or
pseudoaneurysms requiring compression or thrombin injection
therapy, or hematomas requiring transfusion 2 but 4 U)
ot requiring unplanned percutaneous or surgical intervention
nd not resulting in irreversible end organ damage; 2) distal
mbolization treated with embolectomy and/or thrombectomy
nd not resulting in amputation or irreversible end organ
amage; 3) failure of percutaneous access site closure resulting
n interventional (endovascular stent) or surgical correction and
ot associated with death, need for significant blood transfu-
ions (4 U), or irreversible end organ damage.
Major bleeding was defined as a clear site of bleeding that
et any one of the following criteria; bleeding that: 1) caused
Figure 1. CBOT Steps
The steps consist of: (A) localization of entry site with iliac angiogram; (B) arterial
the 10 F-Prostar device (blue arrow); (E) after withdrawal of TAVI delivery sheath
arrow) into sheath over hydrophilic wire (blue arrow); (F) long crossover sheath
TAVI sheath withdrawn into external iliac, appropriately sized peripheral balloon (b
ment; and (H) ﬁnal angiogram performed through crossover sheath (blue arroweath; 2) caused a hospitalization or prolonged hospitalization24 h due to treatment of bleeding; 3) required pericardio-
entesis or an open and/or endovascular procedure for repair or
emostasis; 4) caused permanent disability (e.g., blindness,
aralysis, hearing loss); or 5) required transfusion of 3 U of
lood within a 24-h period. Minor bleeding had to meet all of
he following criteria: 1) bleeding event that did not meet
riteria for major bleeding; 2) clear site for bleeding; and 3) loss
f hemoglobin 3 g/dl or loss of hematocrit 9%.
Angiographic outcomes were prospectively collected at the
ime of the procedure and angiographic endpoints were deter-
ined by consensus from an assessment team composed of 2
nterventional cardiologists and 1 cardiothoracic surgeon. All
linical outcomes were prospectively determined at the time of
he event or at the 30-day follow-up visit.
Statistics. Continuous variables are presented as mean 
D, medians, and percentages.
esults
Between November 2008 and September 2010, 56 consec-
utive suitable patients with severe symptomatic AS under-
went TAVI via the transfemoral approach using a 23-mm
re under ﬂuoroscopy; (C) veriﬁcation of sheath entry site; (D) deployment of
arrow) into common iliac, catheter advanced from contralateral side (red
rrow) advanced from contralateral side over stiff wire (blue arrow); (G) after
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86424-F sheath, respectively) and were percutaneously closed
using the CBOT. Baseline characteristics of the overall
study population are shown in Table 1.
The mean time required to perform the CBOT (from valve
deployment to suturing of the closure device) was 13.3  6.7
min. Successful closure was obtained in 53 patients (94.6%).
Characteristics present in all 3 cases of failure were obesity,
vessel calcification, small vessel diameter, and unusually “high”
arteriotomy access. In the 3 patients who failed closure by the
CBOT/Prostar technique, all 3 had immediate and uneventful
surgical repair aided by intraoperative hemostasis with the
proximally deployed occlusion balloon.
Among the 53 patients who underwent successful closure
with CBOT, primary closure was obtained without subse-
quent post-dilation in 24 cases (42.8% of total), whereas 29
cases needed additional interventions. Among those 29
patients, 26 (46.4% of total) required only subsequent
low-pressure (0.5 atm) balloon inflation at the arteriotomy
site to optimize angiographic outcomes, whereas 3 required
endovascular stenting (5.4% of total). The reasons for
post-dilation or endovascular stenting are shown in Table 2.
In addition to optimizing percutaneous closure device,
CBOT facilitated the acute management of closure device
Table 1. Baseline Characteristics
TAVI (n  56)
Age, yrs 86.1 7.0
Men 32 (57.1%)
Weight, kg 73.4 19.0
Height, cm 165.8 12.0
Body mass index, kg/m2 26.5 5.8
Diabetes mellitus 12 (21.4%)
Hypertension 43 (76.8%)
Hyperlipidemia 35 (62.5%)
Atrial ﬁbrillation 21 (37.5%)
Peripheral vascular disease 7 (12.5%)
Chronic obstructive pulmonary disease 13 (23.2%)
Previous stroke 8 (14.3%)
Previous PCI 15 (26.7%)
Previous CABG 17 (30.3%)
Creatinine before procedure, mg/dl 1.26 0.44
Hemoglobin before procedure, g/dl 11.4 1.5
Hematocrit before procedure, % 35.3 4.2
Left ventricular ejection fraction, % 51 14
Aortic valve area, cm2 0.61 0.16
Mean gradient, mm Hg 46.6 11.6
BNP before procedure, pg/ml 1,345 1,699
STS score 11.9 4.8
EuroScore 29.5 15.4
Sheath size 24-F/22-F 71%/29%
Values are mean SD or n (%).
BNP  brain natriuretic peptide; CABG  coronary artery bypass graft; PCI  percutaneous
coronary intervention; STS  Society of Thoracic Surgeons; TAVI  transcatheter aortic valveimplantation.failure in 3 patients (5.4%). In those patients, the CBOT
allowed optimal hemostasis of 2 external iliac artery perfora-
tions and 1 flow-limiting dissection prior and during urgent
surgical repair.
Importantly, no vascular or bleeding complications have
been associated or related to the realization of the CBOT.
Moreover, no complications were associated with the con-
tralateral access site used for the CBOT. Closure of the
contralateral site was performed in 47 patients (84%)
with a single PerClose Proglide device, in 6 patients
(11%) with an AngioSeal device, and in 3 patients (5%)
by manual compression.
30-day clinical outcomes of CBOT. There were 4 deaths at 30
days, but none were related to CBOT or peripheral vascular
complications (Table 3). Of the 8 major vascular compli-
cations, 3 were associated with unplanned vascular repair
surgery and 3 with unplanned percutaneous intervention
requiring an endovascular stent. There were no major
vascular complications after the patient left the procedure
room during the following 30 days. Of the 56 patients, 14
(25%) required blood transfusions. Six patients (10.7%)
received transfusions for vascular complications (includ-
ing hematomas), whereas 8 (14.3%) others were trans-
fused for reasons unrelated to closure device failure or
vascular access complications (Table 4).
Discussion
The present study is a comprehensive report examining the
results of an adjunctive CBOT in combination with the 10-F
Prostar PCD on the acute angiographic findings and 30-day
clinical outcomes in patients undergoing TAVI using the 23-
or 26-mm Edwards SAPIEN transcatheter valve (22- or 24-F
sheath). The principal findings of the study are: 1) a fully
percutaneous closure combined with adjunctive CBOT is
feasible and safe in most patients undergoing transfemoral
Table 2. Utility of the COBT Among 56 Consecutive TAVI via
Transfemoral Approach
Primary closure 24 (42.8%)
Post-dilation 29 (51.8%)
Balloon angioplasty only 26 (46.4%)
Angiographic dissection 10 (17.9%)
Angiographic extravasation at arteriotomy site 10 (17.9%)
Partial stenosis induced by closure device 6 (10.7%)
Stenting 3 (5.4%)
Vessel perforation 2 (3.6%)
Artery avulsion/dissection 1 (1.8%)
Bridge to surgical repair 3 (5.4%)
Perforation 2 (3.6%)
Dissection (occlusive ﬂap) 1 (1.8%)
Values are n (%).
CBOTcrossoverballoonocclusion technique; TAVI transcatheter aortic valve implantation.TAVI with the 22- or 24-F sheath system; 2) CBOT is
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865associated with a high rate of percutaneous closure device
success and infrequent major bleeding; and 3) CBOT is helpful
in the management of acute vascular complications related to
transfemoral TAVI and was associated with a low rate of
transfusion and urgent vascular repair.
Vascular closure following large-vessel access had previ-
ously been performed utilizing conventional surgical repair
techniques. Recently, complete percutaneous closure has
been shown to be feasible and successful for percutaneous
endograft procedures in patients with abdominal aortic
aneurysms (9,11–13,16–18). The predominant closure
methods involved either a 10-F Prostar device or multiple
6-F ProGlide devices. Due to the high rate of vascular
complications associated with the first generation of TAVI
devices, percutaneous closure techniques have been recently
adapted by many TAVI operators to improve clinical
outcomes, including earlier patient ambulation (10,19,20).
The current study reports a success rate of 94.6% with
the 10-F Prostar PCD when combined with adjunctive
CBOT. These findings are similar to a previous report by
Sharp et al. (20) (85.7%) using similar CBOT methods in
52 patients undergoing TAVI. The slightly higher rate of
success reported in our cohort of patients may represent
Table 3. 30-Day Outcomes
TAVI With CBOT
(n  56)
30-day mortality, all cause 4 (7.1%)
Left ventricular perforation 1 (1.7%)
Stroke/acute respiratory failure 1 (1.7%)
Severe RV failure/severe pulmonary hypertension 1 (1.7%)
Thoracic aortic dissection 1 (1.7%)
Vascular complications* 9 (16.1%)
Major vascular complications 8 (14.3%)
Thoracic aortic dissection 1 (1.7%)
Left ventricular perforation 1 (1.7%)




Minor vascular complications 1 (1.7%)
Hematoma with hemoglobin drop 3 g/dl 1 (1.7%)
Major bleeding* 3 (5.4%)
Minor bleeding* 3 (5.4%)
Patients who needed transfusion 14 (25%)
Patients who needed 3 transfusions 3 (5.4%)
Patients who needed 3 transfusions 11 (19.6%)
Mean hemoglobin drop, g/dl 2.20 0.85
Patients with hemoglobin drop 3 g/dl 9 (16.1%)
Mean hematocrit drop, % 7.0 2.91
Hospitalization duration, mean/median, days 7.8 10.8/6.0
Values are n (%) or mean  SD. *Based on a modified version of the Valve Academic Research
Consortium criteria.
Abbreviations as in Table 2an evolution of CBOT and the more aggressive use ofendovascular interventional techniques to manage vascu-
lar complications.
Major vascular complications are one of the primary
complications of TAVI, and have been reported to occur in
16.2% of patients undergoing TAVI in a recent randomized
trial that included both surgical as well as percutaneous
closure methods (5). We observed major vascular compli-
cations in 14.3% of our patients in whom primary percuta-
neous closure was attempted. Importantly, CBOT was
essential in our experience, not only to facilitate percutane-
ous closure, but also to manage vascular complications. Of
note, 2 of our 8 major vascular complications were unrelated
to vascular access per se (left ventricular perforation and
ascending aortic dissection) and were due to other proce-
dural technical considerations.
One of the main advantages of CBOT is the ability to
rapidly recognize and efficiently manage vascular complica-
tions associated with transfemoral TAVI (Fig. 2). This
advantage may ultimately result in less bleeding and fewer
transfusions. In the present study, a subsequent percutane-
ous intervention was performed in 51.8% of the total
population, either to optimize a final result (small extrava-
sation at the arteriotomy site, nonocclusive dissection, or
stenosis induced by the Prostar sutures), or to manage
percutaneously a more serious complication (occlusive dis-
section, artery avulsion, or vessel perforation). Additionally,
in the 3 patients who subsequently underwent open surgical
repair, CBOT was used to achieve hemostasis intraopera-
tively. It is notable that the 30-day rate of major bleeding in
our cohort was 5.4%, compared with 16.8% in the
nonoperative arm of the PARTNER trial (5). Further-
more, among our 6 patients who had major vascular
complications related to the access site, only 3 required
transfusions, reflecting the potential value of the CBOT
to facilitate hemostasis. Interestingly, overall in this
patient cohort, most of the transfusions given during the
Table 4. Reasons for Blood Transfusions During the Index Hospitalization
Vascular complications 6 (42.9%)
Major vascular complications* 5 (35.7%)
Aortic thoracic dissection 1 (7.1%)
LV perforation 1 (7.1%)
Unplanned surgical repair 2 (14.3%)
Unplanned percutaneous intervention (endovascular stent) 1 (7.1%)
Minor vascular complications* 1 (7.1%)
Hematoma with hemoglobin drop 3 g/dl 1 (7.1%)
Others 8 (57.1%)
Gastrointestinal blood loss 3 (21.4%)
Genitourinary blood loss 2 (14.3%)
Inﬂammatory anemia/sepsis 1 (7.1%)
No other causes identiﬁed 2 (14.3%)
Values are n (%). *Based on a modified version of the Valve Academic Research Consortium
criteria.LV left ventricle.
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866Figure 2. Management of Access Site Utilizing Crossover Balloon Occlusion Technique
(A) Dissection at access site (left, arrow), which is resolved following prolonged balloon inﬂation (right). (B) Closure device induced stenosis at access site fol-
lowing closure (left, arrow), which is resolved after 5-min balloon inﬂation (right). (C) Perforation of external iliac (left, arrow) which is treated successfully with
a covered stent (right, delineation of stent length).
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867index hospitalization were unrelated to vascular compli-
cations or to the access site.
Lately, some TAVI operators have adopted a “modified”
crossover technique, with placement of a coronary wire
(0.014 inch) in the superficial femoral artery from the
contralateral site before insertion of the TAVI sheath. This
allows access to the puncture site in case of a major vascular
event without the need for a 7- or 8-F crossover sheath
before TAVI sheath removal. However, this technique does
not allow optimal management of the access site in patients
with a suboptimal closure using an endovascular occlusion
balloon as described in this paper. Furthermore, in case of
severe vascular complications, this technique will require an
exchange of the 0.014-inch wire for a larger crossover sheath
and occlusive balloon, which may be time consuming and
therefore result in major blood loss.
Study limitations. This study represents the experience of 4
TAVI operators performing procedures at a single academic
center. Despite the prospective nature of this study, patients
were strictly selected before their enrollment in the random-
ized PARTNER trial based on the suitability of vascular
access for TAVI via the transfemoral route. Appropriate
screening and patient selection is mandatory for the success
of the PCD technique with a large-diameter sheath, and
findings of the current study cannot be generalized to
patients with severe peripheral disease. The results of this
report should therefore be considered hypothesis generat-
ing, especially given the absence of a direct comparison with
standard surgical repair or with percutaneous closure with-
out the use of CBOT. Thus, prospective, randomized trials
comparing surgical repair to the CBOT/PCD technique
would be valuable to further evaluate the incremental
clinical benefit of percutaneous closure in patients undergo-
ing TAVI via transfemoral access.
Conclusions
Adjunctive CBOT combined with the Prostar PCD is
feasible and resulted in a controlled, safe, and successful
percutaneous closure in most patients undergoing TAVI.
This technique was associated with low rates of access site
complications and bleeding events. A PCD-enabled tech-
nique aided by CBOT after TAVI may be a viable alterna-
tive to conventional surgical repair when used in appropri-
ately selected patients.
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